Myogenic IGFBP5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosis

Abstract Background Mesenchymal stromal cells belong to a diverse collection of cells in different states that are poorly characterized in soft-tissue sarcomas. In this study, we explored tumor growth-regulatory signaling between differentially educated non-malignant mesenchymal stromal cells and ma...

Full description

Saved in:
Bibliographic Details
Main Authors: Yue Zhang, Karim Katkhada, Liu Zhen Meng, Binbin Zhao, Shanlin Tong, Wiem Chaabane, Aditi Kallai, Nicholas P. Tobin, Arne Östman, Alessandro Mega, Monika Ehnman
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Cell Communication and Signaling
Subjects:
Online Access:https://doi.org/10.1186/s12964-025-02171-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849699174889553920
author Yue Zhang
Karim Katkhada
Liu Zhen Meng
Binbin Zhao
Shanlin Tong
Wiem Chaabane
Aditi Kallai
Nicholas P. Tobin
Arne Östman
Alessandro Mega
Monika Ehnman
author_facet Yue Zhang
Karim Katkhada
Liu Zhen Meng
Binbin Zhao
Shanlin Tong
Wiem Chaabane
Aditi Kallai
Nicholas P. Tobin
Arne Östman
Alessandro Mega
Monika Ehnman
author_sort Yue Zhang
collection DOAJ
description Abstract Background Mesenchymal stromal cells belong to a diverse collection of cells in different states that are poorly characterized in soft-tissue sarcomas. In this study, we explored tumor growth-regulatory signaling between differentially educated non-malignant mesenchymal stromal cells and malignant cells in pediatric rhabdomyosarcoma (RMS). Methods Xenograft experiments demonstrated that non-malignant stromal cells influence tumor behavior. Gene expression analysis identified deregulated genes, which were further studied using cell culture assays and patient data. Clinicopathological correlations were made in a discovery cohort (N = 147) and a validation cohort (N = 101). Results The results revealed transiently suppressive paracrine effects of orthotopic stromal cells derived from skeletal muscle. These effects were lost when the stromal cells were exposed to RMS cells, either short-term in vitro, or long-term in hindlimb muscle in vivo. High resolution microarray-based Clariom D gene expression analysis identified insulin-like growth factor binding protein 5 (IGFBP5) as the top upregulated gene in RMS cells exposed to naïve stromal cells, and effects on growth arrest, caspase 3/7 activation, and myogenic cell identity were demonstrated in functional assays. Furthermore, IGFBP5 associated with the caspase 3 substrate growth arrest specific protein 2 (GAS2), lower disease stage and favorable survival in patient cohorts. Conclusions This study uses functional modeling and omics approaches to identify IGFBP5 as a candidate mediator of anti-tumor growth mechanisms originating from tumor-neighboring mesenchymal stromal cells. Tumors of mesenchymal origin, such as RMS, are known for their heterogeneity, and this could potentially pose a limitation to the study. However, a clinical relevance is emphasized by consistent findings across patient cohorts. These insights pave the way for novel therapeutic strategies modulating activities of stromal cell subsets at primary and metastatic sites in RMS. Graphical Abstract
format Article
id doaj-art-2c8db3f6ed0644eebf1e4f00bcfa5f0d
institution DOAJ
issn 1478-811X
language English
publishDate 2025-04-01
publisher BMC
record_format Article
series Cell Communication and Signaling
spelling doaj-art-2c8db3f6ed0644eebf1e4f00bcfa5f0d2025-08-20T03:18:41ZengBMCCell Communication and Signaling1478-811X2025-04-0123111810.1186/s12964-025-02171-6Myogenic IGFBP5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosisYue Zhang0Karim Katkhada1Liu Zhen Meng2Binbin Zhao3Shanlin Tong4Wiem Chaabane5Aditi Kallai6Nicholas P. Tobin7Arne Östman8Alessandro Mega9Monika Ehnman10Department of Oncology-Pathology, Karolinska InstitutetDepartment of Oncology-Pathology, Karolinska InstitutetDepartment of Oncology-Pathology, Karolinska InstitutetDepartment of Oncology-Pathology, Karolinska InstitutetDepartment of Oncology-Pathology, Karolinska InstitutetDepartment of Oncology-Pathology, Karolinska InstitutetDepartment of Oncology-Pathology, Karolinska InstitutetDepartment of Oncology-Pathology, Karolinska InstitutetDepartment of Oncology-Pathology, Karolinska InstitutetDepartment of Oncology-Pathology, Karolinska InstitutetDepartment of Oncology-Pathology, Karolinska InstitutetAbstract Background Mesenchymal stromal cells belong to a diverse collection of cells in different states that are poorly characterized in soft-tissue sarcomas. In this study, we explored tumor growth-regulatory signaling between differentially educated non-malignant mesenchymal stromal cells and malignant cells in pediatric rhabdomyosarcoma (RMS). Methods Xenograft experiments demonstrated that non-malignant stromal cells influence tumor behavior. Gene expression analysis identified deregulated genes, which were further studied using cell culture assays and patient data. Clinicopathological correlations were made in a discovery cohort (N = 147) and a validation cohort (N = 101). Results The results revealed transiently suppressive paracrine effects of orthotopic stromal cells derived from skeletal muscle. These effects were lost when the stromal cells were exposed to RMS cells, either short-term in vitro, or long-term in hindlimb muscle in vivo. High resolution microarray-based Clariom D gene expression analysis identified insulin-like growth factor binding protein 5 (IGFBP5) as the top upregulated gene in RMS cells exposed to naïve stromal cells, and effects on growth arrest, caspase 3/7 activation, and myogenic cell identity were demonstrated in functional assays. Furthermore, IGFBP5 associated with the caspase 3 substrate growth arrest specific protein 2 (GAS2), lower disease stage and favorable survival in patient cohorts. Conclusions This study uses functional modeling and omics approaches to identify IGFBP5 as a candidate mediator of anti-tumor growth mechanisms originating from tumor-neighboring mesenchymal stromal cells. Tumors of mesenchymal origin, such as RMS, are known for their heterogeneity, and this could potentially pose a limitation to the study. However, a clinical relevance is emphasized by consistent findings across patient cohorts. These insights pave the way for novel therapeutic strategies modulating activities of stromal cell subsets at primary and metastatic sites in RMS. Graphical Abstracthttps://doi.org/10.1186/s12964-025-02171-6RhabdomyosarcomaMesenchymal stromal cellsIGFBP5ApoptosisGrowth arrest
spellingShingle Yue Zhang
Karim Katkhada
Liu Zhen Meng
Binbin Zhao
Shanlin Tong
Wiem Chaabane
Aditi Kallai
Nicholas P. Tobin
Arne Östman
Alessandro Mega
Monika Ehnman
Myogenic IGFBP5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosis
Cell Communication and Signaling
Rhabdomyosarcoma
Mesenchymal stromal cells
IGFBP5
Apoptosis
Growth arrest
title Myogenic IGFBP5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosis
title_full Myogenic IGFBP5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosis
title_fullStr Myogenic IGFBP5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosis
title_full_unstemmed Myogenic IGFBP5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosis
title_short Myogenic IGFBP5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosis
title_sort myogenic igfbp5 levels in rhabdomyosarcoma are nourished by mesenchymal stromal cells and regulate growth arrest and apoptosis
topic Rhabdomyosarcoma
Mesenchymal stromal cells
IGFBP5
Apoptosis
Growth arrest
url https://doi.org/10.1186/s12964-025-02171-6
work_keys_str_mv AT yuezhang myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis
AT karimkatkhada myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis
AT liuzhenmeng myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis
AT binbinzhao myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis
AT shanlintong myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis
AT wiemchaabane myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis
AT aditikallai myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis
AT nicholasptobin myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis
AT arneostman myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis
AT alessandromega myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis
AT monikaehnman myogenicigfbp5levelsinrhabdomyosarcomaarenourishedbymesenchymalstromalcellsandregulategrowtharrestandapoptosis